SFI
HRTX icon

Susquehanna Fundamental Investments’s Heron Therapeutics HRTX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,727
Closed -$32.5K – 964
2024
Q1 		$32.5K Buy
+11,727
New +$29.5K ﹤0.01% 665
2023
Q4 		– Sell
-116,363
Closed -$120K – 184
2023
Q3 		$120K Sell
116,363
-109,539
-48% -$156K 0.01% 344
2023
Q2 		$262K Sell
225,902
-24,514
-10% -$43.7K 0.01% 545
2023
Q1 		$378K Sell
250,416
-9,365
-4% -$23.5K 0.01% 739
2022
Q4 		$649K Buy
+259,781
New +$837K 0.01% 783
2022
Q1 		– Sell
-13,319
Closed -$122K – 1596
2021
Q4 		$122K Sell
13,319
-116,728
-90% -$1.19M ﹤0.01% 1316
2021
Q3 		$1.39M Buy
130,047
+75,959
+140% +$925K 0.03% 733
2021
Q2 		$839K Buy
+54,088
New +$860K 0.02% 932

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Susquehanna Fundamental Investments's HRTX Position: Q2 2024 in Review

Susquehanna Fundamental Investments sold out of Heron Therapeutics (HRTX) in Q2 2024, closing a stake of 11,727 shares — an estimated $32.5K sold.

Susquehanna Fundamental Investments first reported a position in HRTX in Q2 2021 and held it in 8 quarters. The position peaked at $1.39M in Q3 2021. 190 funds tracked by Wall St. Rank hold HRTX as of Q2 2024.

  • Susquehanna Fundamental Investments reported no remaining Heron Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 11,727 Heron Therapeutics shares in Q2 2024, an estimated $32.5K.
  • Susquehanna Fundamental Investments first reported a position in Heron Therapeutics in Q2 2021 and held it in 8 quarters.
  • Susquehanna Fundamental Investments's Heron Therapeutics position peaked at $1.39M in Q3 2021.
  • 190 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2024.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2024, filed 15 Aug 2024.